# Columbia University Minority/Underserved Site NCI Community Oncology Research Program

> **NIH NIH UG1** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2021 · $1,021,013

## Abstract

PROJECT SUMMARY
The Herbert Irving Comprehensive Cancer Center’s Minority/Underserved National Community Oncology
Research Program at Columbia University Irving Medical Center (HICCC/CUIMC/MU-NCORP) has established
a robust infrastructure that facilitates the identification, activation and participation in NCORP Research Base
clinical trials. The overall goal of the HICCC/CUIMC/MU-NCORP is to provide the best in cancer care to the
minority/undeserved population that surrounds our cancer center. The specific aims of our program are to 1)
Provide and enhance access for our community of patients and healthcare providers to a portfolio of NCI Clinical
Trials Network (NCTN/NCORP) trials, specifically in the four components of cancer control, cancer prevention
and screening, cancer care delivery (CCD) research and cancer treatment (Phase I, II, III) as well as tissue
acquisition; 2) Enhance the accrual of minority and underserved patients onto these trials by promoting the
accessibility and availability of the trial portfolio and identifying and reducing accrual barriers to meet the needs
of our community, 3) Lead, participate, and promote NCORP/NCTN research base studies across the cancer
care continuum with a particular focus on studies that reduce healthcare disparities, and 4) Collaborate and
contribute to the NCI NCORP-wide activities. Over the past four years, this strong infrastructure has led to many
accomplishments. Our MU-NCORP portfolio consists of over 150 trials, and we have enrolled over 500 patients
to Cancer Control and Prevention, Cancer Care Delivery and Therapeutic Trials. We have consistently exceeded
the minimum 30% accrual target for minority and underserved patient populations. In addition, we have taken
leadership roles within the research bases and lead many trials. By facilitating the enrollment and participation of
minority and underserved cancer patients into high impactful clinical trials, we will achieve our ultimate goal of
improving survival and quality of life of all individuals regardless of age, race, ethnicity, gender, sexual orientation
or socioeconomic status.

## Key facts

- **NIH application ID:** 10232160
- **Project number:** 5UG1CA189960-08
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Andrew B Lassman
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,021,013
- **Award type:** 5
- **Project period:** 2014-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10232160

## Citation

> US National Institutes of Health, RePORTER application 10232160, Columbia University Minority/Underserved Site NCI Community Oncology Research Program (5UG1CA189960-08). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10232160. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*